Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
34
resultados
Última actualización
14/09/2026 [08:19:00]
Resumen de: US20260250363A1
0000 Provided herein are antibodies or antigen binding fragments thereof having a binding specificity for SARS-CoV-2 spike protein, and bispecific antibodies comprising a first and a second antigen binding region that bind to SARS-CoV-2 spike protein. Also provided herein are pharmaceutical compositions comprising the antibodies, antigen binding fragments thereof, or bispecific antibodies.
Resumen de: US20260251661A1
A method for testing a diseased state of vasculitis and a method for testing an exacerbation risk of COVID-19, the method including: detecting or quantifying, in a blood sample collected from a subject, (1) a No. 1 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 23 to 25 kDa, and/or (2) a No. 2 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 16 to 20 kDa.
Resumen de: WO2026178292A1
Microneedle patches or microneedle array patches (MAPs) offer a convenient method to intradermally deliver drugs and vaccines. Embodiments include MAPs that overcome the limitations of conventional MAPs. In aspects, the MAPs include (a) a base, (b) an adhesive region and (c) a plurality of needles on a surface of the base. The needles can comprise a medicament (e.g., a therapeutic or vaccine). In aspects, the medicament is a circular RNA vaccine that elicits an immune response against SARSCoV-2.
Resumen de: EP4796155A2
Provided herein are devices and methods that relate to ventilation and respiration. In one embodiment, a ventilator device comprising a fluidic amplifier with one or more coaxially aligned components, where there are no internal moving components. In another embodiment, a device and related methods for treating a patient who needs ventilation such as after infection by the coronavirus Covid-19.
Resumen de: EP4266057A1
The invention relates to an in vitro method for the detection of inflammation caused by an acute COVID-19 infection, long COVID and/or PIMS, wherein the level of kynurenine in a body fluid is determined and wherein the value of kynurenine measured in the patient to be diagnosed is compared with the average value obtained from a comparable cohort of persons who do not suffer from said diseases, whereby the value of kynurenine in patients is increased.
Resumen de: US20260242448A1
The present disclosure provides a broad-spectrum bispecific antibody against novel coronaviruses, comprising a first targeting domain D1 targeting a first epitope of a SARS-CoV-2 RBD domain, and a second targeting domain D2 targeting a second epitope of the SARS-CoV-2 RBD domain. The bispecific antibody of the present disclosure has a broad-spectrum neutralizing activity and can effectively neutralize SARS-CoV-2 and various highly infectious and harmful SARS-CoV-2 variant strains, thus showing significant application value in the prevention, treatment, and/or detection of infections caused by novel coronaviruses.
Resumen de: US20260240166A1
0000 Biologically active ion-exchange polymer salts are made by exchanging biologically active ionic agents onto organic ion exchange polymers. The activated polymers are uniquely surface active for use in a wide range of antibacterial, antifungal and antiviral coatings, materials, and devices, to minimize or prevent pathogen transmission and/or infection of a susceptible individual such as a patient in a hospital. The resultant coatings, materials, and devices are the foundation of a system enabling the construction of spheres of protection, for example to protect against transmission of COVID-19 (SARS-COV-2) coronaviruses and other viral and fungal pathogens in a clinical or institutional environment, for example hospitals, community institutions, cruise ships, and long-term care facilities. The activated ion-exchange polymer salts are process stable, allowing size reduction and formulation of the resulting powders into bulk polymers or polymer precursors to produce stable, biologically active polymer composites, including antimicrobial and antiviral polymer composites.
Resumen de: US20260242763A1
0000 A fully human ACE2-Fc fusion protein, a pharmaceutical composition, preparation and kit containing same, and a nasal spray containing the fusion protein. Also provided is a use of the fusion protein for broad-spectrum prevention of coronavirus infections, such as infections with coronavirus SARS-CoV-2 and known and unknown variants thereof, including but not limited to original Hu-1, alpha, beta, gamma, delta, mu, omicron, JN.1, and/or other future strains. Also provided are a method for producing the fusion protein, and a method for using the fusion protein to prevent and/or treat infections with coronavirus SARS-CoV-2 and known and unknown variant strains thereof. Further provided is a use of the fusion protein and the pharmaceutical composition and preparation containing same for preventing the spread of coronavirus SARS-CoV-2 and known and unknown variant strains in infected subjects.
Resumen de: US20260242881A1
0000 Methods are provided for determining whether a subject has been exposed to or infected with Bacillus anthracis, SARS-CoV-2, influenza A, human immunodeficiency virus type 1 (HIV-1), methicillin-susceptible Staphylococcus aureus (MSSA), or methicillin-resistant Staphylococcus aureus (MRSA), or has been exposed to an organophosphate (OP). Such methods include determining the measuring methylation status of numerous differentially methylated regions (DMRs) in the genomic DNA of particular PBMCs, such as those provided in Table 1, and in some examples also determining an amount of accessible chromatin in the isolated immune cells. Also provided are nucleic acid probes, arrays, solid supports (such a chip or nanosphere) and kits that can be used with such methods.
Resumen de: US20260240794A1
The present invention is directed to compositions and methods for treating infection with SARS-CoV-2 virus and its sequelae through inhibition of the β-arrestin (arrestin-2) pathway by use of β-adrenergic inverse agonists, particularly including nadolol. The compositions and methods can also employ additional agents to block infection with SARS-CoV-2 virus or inhibit inflammation, particularly inflammation affecting the respiratory tract.
Resumen de: US20260240922A1
0000 The purpose of the present invention is to provide a composition for preventing or treating a chemosensory disorder. The present invention provides a composition for preventing or treating a chemosensory disorder, comprising a lactic acid bacterium. The chemosensory disorder can be a chemosensory disorder that occurs after SARS-CoV-2 viral infection. The present invention is advantageous in that lactic acid bacteria can be used as a functional ingredient that imparts a preventive or therapeutic effect against a chemosensory disorder, and a pharmaceutical product or a food product that is safe for mammals including humans can be provided.
Resumen de: WO2026172365A1
This study presents the synthesis of novel Benzodiazocine analogues and their potential as potent antiviral agents. Benzodiazocines, featuring an eight-membered fused bicyclic core, adhere to Lipinski's rule of five, ensuring drug-like properties. Structural modifications via Structure-Activity Relationship (SAR) enhanced their antiviral efficacy. In vitro assays, including cytotoxicity analysis and RT-qPCR-based studies, evaluated activity against SARS- CoV-2. Several analogues demonstrated promising antiviral potential, contributing to the ongoing pursuit of effective therapeutics against viral infections.
Resumen de: US20260242880A1
Provided are methods for co-extraction of DNA or RNA from two or more pathogens (such as Mycobacterium tuberculosis (Mtb) and SARS-CoV-2 (SC2)) in a sample. Also provided are assays for identifying a pathogen (such as Tuberculosis (TB)) directly from a sample.
Resumen de: US20260242447A1
COVID-19 results from the infection of the SARS-CoV-2 virus and has spread quickly to literally infected the world. Although coronavirus spike proteins can recognize a broad range of host cell-surface proteins, inhibiting spike protein binding to a survival factor called GRP78 results in a significant reduction in SARS-CoV-2 attachment, entry and replication in lung and kidney cells. This inhibition is accomplished with a novel type of inhibitor that potently blocks the binding of SARS-CoV-2 spike protein and whole virus to surface-bound GRP78. These novel GRP78 inhibitors also down regulate cytokines (IL10, IL6), immune co-inhibitory checkpoint proteins (PD-L1, B7H3, B7H4), and up regulate immune co-stimulatory proteins (MHC-II, CD-86) resulting in the reduction of the immune suppressive nature of infected lung alveolar epithelial cells in vitro and in vivo. Finally, these novel GRP78 inhibitors inhibit the hyperfibrinolysis of infected lung cells by reducing the activation of plasmin on cell surfaces.
Resumen de: AU2026210797A1
WZF000PTEA01D2300070 Specifically disclosed are a core amino acid sequence group for the targeted recognition of anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs, and the use thereof. The core amino acid sequence group for the targeted recognition of the anti-SARS-CoV-2 neutralizing antibodies 5 N-IgY-pAbs comprises 15 amino acid sequences located in an S-ECD domain and 5 amino acid sequences located in a non-structural protein (NSP) domain, and can be applied to the detection of SARS-CoV-2, and the designing of treatment targets and designing of vaccine targets. In the above amino acid sequence group, it is found that P272 in only one aa261-275 sequence of an S protein is a residue with a low-frequency mutation, and the remaining 19 sequences are 10 conservative amino acid sequences, do not contain the currently discovered virus mutation sites, and are highly conservative, which can effectively cope with the unfavorable situation of high-frequency mutation of SARS-CoV-2 at present. WZF000PTEA01D2300070 Specifically disclosed are a core amino acid sequence group for the targeted recognition of anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs, and the use thereof. The core amino acid 5 sequence group for the targeted recognition of the anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs comprises 15 amino acid sequences located in an S-ECD domain and 5 amino acid sequences located in a non-structural protein (NSP) domain, and can be applied to the detection of SARS-CoV-2, a
Resumen de: US20260242415A1
0000 The present invention relates to novel cyclic peptides. The peptides bind viral proteins, particularly a conserved site on the SARS-CoV-2 spike protein, and therefore the peptides can be useful for neutralizing SARS-CoV-2 variants. Accordingly, the invention also relates to medical use of the peptides.
Resumen de: WO2022117221A1
The present application relates to the use of a phthalazinedione in the prevention or treatment of sequelae of a SARS-CoV-2 infection. Pharmaceutical compositions, combinations, advantageous formulation techniques and a method of treatment are disclosed.
Resumen de: PL451191A1
Przedmiotem zgłoszenia jest liposomowy preparat, do stosowania w leczeniu COVID-19.
Resumen de: US20260234224A1
The present disclosure relates to antibodies and uses thereof for treating, preventing, and detecting coronavirus infection.
Resumen de: US20260232749A1
A polyphenol-rich composition is orally administered to alleviate a sign or symptom of a post-viral syndrome, and preferably post-COVID syndrome. Most typically, the composition comprises at least 50 wt % total catechins, at least 20 wt % total chlorogenic acids, and optionally up to 30 wt % total supplemental antioxidants. The composition may be formulated from a green coffee bean extract, a green tea extract, a turmeric extract, a tart cherry or extract thereof, a broccoli or extract thereof, and a kale or extract thereof. Notably, such compositions were effective in individuals post SARS-CoV2 infection to reduce proinflammatory cytokines and interleukins, increase NOHb, and to reduce reactive oxygen species due to mitochondrial dysfunction, iNOS activity, and NOX2 activity.
Resumen de: WO2026169917A1
Provided are engineered SARS-CoV-2 virus-like particles (VLPs) and methods of making and using the VLPs for mRNA delivery. A 3 plasmid (3P) VLP system displays ~7-fold higher viral entry efficiency compared to VLPs formed by co-transfection with 4 plasmids. A 2 plasmid (2P) VLP system is provided where one vector carries the viral surface glycoprotein and the second carries the remaining SARS-CoV-2 structural proteins and reporter gene. The VLPs can carry up to four transgenes, including functional Cas9 mRNA for genome editing. Gene editing of specific target cell types is performed modifying VLP tropism. Successful mRNA delivery to mouse lungs shows that the SARS-CoV-2 VLPs can overcome natural biological barriers to enable pulmonary gene delivery.
Resumen de: WO2026165666A1
The present disclosure provides a method for treating long CO VID ( e.g., severe long CO VID) or at least one symptom thereof in a subpopulation of subjects displaying a combination of biomarkers namely a blood level of secreted B-cell activating factor and of membrane BAFF in white blood cells higher than a corresponding reference level; and at least one of blood level of precursor- like marginal zone B-cell populations, zonulin, anti-Mi-2 nuclear antigen autoantibodies, anti-SmD autoantibodies, anti-Ul-snRNP-A autoantibodies, anti-RCN2 autoantibodies, lipopolysaccharide-binding protein (LBP), and p-D-glucan higher than a corresponding reference level, and APRIL lower than a corresponding reference level, comprising administering a therapeutically effective amount of a BAFF inhibitor to the subject. It also provides a method of diagnosing a subject as having long CO VID using the combination of biomarkers and a diagnosis kit comprising ligands for the biomarkers.
Resumen de: US20260234738A1
0000 The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
Resumen de: WO2026165610A1
The present invention relates to a pharmaceutical composition comprising the lipopeptide adjuvant Cys-Dipalmitoyl-Ser-Lys-Lys-Lys-Lys-PEG2-NH2 (otherwise referred to as dipalmitoyl- S-glyceryl-cysteine or Pam2Cys), an antigen, and mannitol, for the treatment and/or prevention of respiratory infections. Disclosed herein, is NoVCoV, a nasal dry powder vaccine that provides a novel and stable alternative to traditional liquid vaccines. This formulation is not only effective for preventing and/or treating COVID-19 but is also adaptable for addressing other respiratory infections.
Nº publicación: US20260232725A1 13/08/2026
Solicitante:
CONTRACTOR CYRUS DARIUS [US]
Contractor Cyrus Darius
Resumen de: US20260232725A1
0000 This invention provides a method for the therapeutic inhalation of hypochlorous acid (HOCl) to treat respiratory infections, reduce lung inflammation, and eliminate airborne pathogens in humans and animals. It describes controlled delivery of HOCl (10-50 ppm) via nebulizers, humidifiers, CPAP devices, ventilators, and direct tracheal instillation to improve oxygenation, break down mucus, and prevent secondary infections. The stabilized HOCl formulation ensures safety and efficacy, distinguishing it from surface disinfection applications. The method leverages HOCl's natural antimicrobial, anti-inflammatory, and mucolytic properties for direct respiratory treatment without toxicity or lung irritation. Applications include treating pneumonia, COVID-19, asthma, bronchitis, and ventilator-associated infections, as well as reducing airborne pathogen transmission in enclosed spaces. The invention presents a novel, non-toxic, and cost-effective approach to respiratory care, enhancing both individual treatment and public health disease mitigation.
BOPI
Sede Electrónica
